Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study.

Trial Profile

Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2010

At a glance

  • Drugs Eplivanserin (Primary)
  • Indications Fibromyalgia; Sleep disorders
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Oct 2008 Official title updated from ClinicalTrials.gov record.
    • 15 Nov 2007 Eplivanserin is expected to be launched in 2009.
    • 19 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top